ArticleNeurogenetics2026
Association of TRPM7 gene mutation with familial vestibular migraine.
Article in Neurogenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Vestibular migraine (VM) is a common neurological disorder characterized by headache and vestibular symptoms, with its genetic mechanism not yet fully elucidated. We aimed to explore the association of TRPM7 gene mutation with familial vestibular migraine. A three-generation VM pedigree from Jinhua, China (4 affected individuals/2 healthy controls) was enrolled for neurological examinations and clinical differential diagnosis. Peripheral blood DNA was extracted using the QIAamp DNA extraction kit, followed by quality control and whole-exome sequencing (WES) performed with the Agilent SureSelect V7 platform. Variant calling was conducted using GATK (v4.3) HaplotypeCaller. Candidate variants were filtered by gnomAD East Asian population frequency (MAF < 0.01) and co-segregation analysis. Pathogenicity was assessed and the TRPM7 c.3526 C > T mutation was ultimately validated by Sanger sequencing. All four VM patients manifested recurrent pulsatile headaches (unilateral/bilateral, lasting 4–48 h) accompanied by nausea/vomiting or photophobia/phonophobia. Among them, two cases presented visual aura and one exhibited concomitant tinnitus. Vestibular symptoms included rotational vertigo (duration: 5 min to 6 h). WES identified a heterozygous nonsense mutation (TRPM7 c.3526 C > T, gnomAD East Asian MAF = 0.000006) in all affected individuals. Bioinformatics analysis revealed that this mutation resulted in C-terminal truncation of the protein, affecting the coiled-coil and kinase domains. Pathogenicity prediction scores unanimously supported its disease-causing potential (CADD = 35.2, MutationTaster = 1.0). Structural modeling demonstrated that the mutation reduced protein stability (ΔΔG = − 2.1 kcal/mol) and impaired Mg²⁺ binding affinity. The TRPM7 c.3526 C > T mutation is associated with familial VM and results in protein truncation that is predicted to affect ion channel–kinase function.
Indexed as
Identifiers
41735710What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.